首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials.
【24h】

Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials.

机译:使用高度灵敏的测定方法对慢性心力衰竭患者的肌钙蛋白T进行连续测量:来自2项大型随机临床试验的数据。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Cardiac troponins are emerging as important prognostic markers in chronic cardiovascular conditions like stable coronary artery disease or chronic heart failure (HF). Less is known about the relation between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF. We determined the association between changes over time in hs-cTnT and outcome in patients with chronic HF. METHODS AND RESULTS: We analyzed 5284 patients with chronic HF from 2 independent randomized clinical trials, the Valsartan Heart Failure Trial (Val-HeFT) (n=4053) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial (n=1231). hs-cTnT was measured at randomization and after 3 months (GISSI-HF) or 4 months of follow-up (Val-HeFT). The association between changes over time of hs-cTnT and various outcomes was tested in multivariable models. In both studies, increases in hs-cTnT levels over time were associated with age, diabetes mellitus, worsening of renal function (reduction in estimated glomerular filtration rate), and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations. Increases in hs-cTnT concentrations were associated with all-cause mortality (incidence rates, 8.19 [7.51-8.88] and 6.79 [5.98-7.61] per 100 person-years in Val-HeFT and GISSI-HF, respectively, with hazard ratios [95% confidence intervals] of 1.59 [1.39-1.82] and 1.88 [1.50-2.35]) after adjustment for conventional risk factors and baseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide. Changes in hs-cTnT concentration modestly improved prognostic discrimination beyond baseline values for fatal outcomes only. CONCLUSIONS: Despite very low circulating concentrations, changes in hs-cTnT concentrations over time are robust predictors of future cardiovascular events in patients with chronic HF but add limited prognostic discrimination. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00336336.
机译:背景:心肌肌钙蛋白在稳定的冠状动脉疾病或慢性心力衰竭(HF)等慢性心血管疾病中正成为重要的预后标志物。关于高敏感性心脏肌钙蛋白T(hs-cTnT)的连续测量与HF未来事件之间的关系了解的很少。我们确定了hs-cTnT随时间的变化与慢性HF患者预后之间的关联。方法和结果:我们从2项独立的随机临床试验,Valsartan心力衰竭试验(Val-HeFT)(n = 4053)和Gruppo Italiano per lo del Studio Sopravvivenza nell'Insufficienza Cardiaca-Heart衰竭( GISSI-HF)试用(n = 1231)。 hs-cTnT在随机分组和3个月(GISSI-HF)或4个月随访(Val-HeFT)后进行测量。在多变量模型中测试了hs-cTnT随时间的变化与各种结果之间的关联。在两项研究中,hs-cTnT水平随时间的升高与年龄,糖尿病,肾功能恶化(估计的肾小球滤过率降低),基线以及N端前脑利钠肽浓度升高有关。 Val-HeFT和GISSI-HF中每100人年的hs-cTnT浓度升高与全因死亡率相关(发生率分别为8.19 [7.51-8.88]和6.79 [5.98-7.61],风险比[调整常规危险因素以及hs-cTnT和N末端脑利钠肽的基线水平后,95%置信区间]为1.59 [1.39-1.82]和1.88 [1.50-2.35]。 hs-cTnT浓度的变化适度地改善了仅对致命结果而言超出基线值的预后判断力。结论:尽管循环血浓度很低,但hs-cTnT浓度随时间的变化是慢性HF患者未来心血管事件的有力预测指标,但预后判断能力有限。临床试验注册:http://www.clinicaltrials.gov。唯一标识符:NCT00336336。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号